The British Journal of Rheumatology, Vol 37, 1123-1125, Copyright © 1998 by British Society for Rheumatology
T Yamamoto, Y Sawada, I Katayama and K Nishioka
OBJECTIVE: Nitric oxide (NO) is an important mediator of immune and
inflammatory responses, and has recently been suggested to play some role
in the pathogenesis of autoimmune disorders. In this study, we have
examined whether peripheral blood mononuclear cells (PBMC) from patients
with systemic sclerosis (SSc) produce higher levels of NO spontaneously or
in response to several stimulations in vitro. METHODS: PBMC were obtained
from 14 patients with SSc and 15 normal volunteers. Release of NO after
stimulation with lipopolysaccharide (LPS), interleukin-lbeta (IL-1beta),
tumour necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma)
was determined by Griess reagents. RESULTS: PBMC from SSc patients
exhibited a higher level of spontaneous release of NO (13.4+/-3.8 microM)
than those from control subjects (8.9+/-1.6 microM), but without
significance. Incubation of PBMC for 24 h with stimulants caused an
increase in NO production both in normal subjects and SSc patients.
Stimulation with 10 U/ml IL-1beta induced a significantly increased NO
production in SSc patients (22.1+/-6.6 microM) compared with normal
subjects (12.3+/-4. microM) (P < 0.05); however, in contrast, incubation
with other stimulants showed no significant differences in NO production
between SSc patients and normal subjects. CONCLUSION: These results suggest
the abnormal regulation of NO production in PBMC of scleroderma patients in
response to IL-1beta, which might contribute, in part, to the fibrotic
process in SSc.
ORIGINAL PAPERS
Increased production of nitric oxide stimulated by interleukin-1beta in peripheral blood mononuclear cells in patients with systemic sclerosis
Department of Dermatology, Tokyo Medical and Dental University School of Medicine, Japan.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Matucci Cerinic and M. B. Kahaleh Beauty and the Beast. The nitric oxide paradox in systemic sclerosis Rheumatology, August 1, 2002; 41(8): 843 - 847. [Full Text] [PDF] |
||||
![]() |
R. E. Girgis, M. K. Gugnani, J. Abrams, and M. D. Mayes Partitioning of Alveolar and Conducting Airway Nitric Oxide in Scleroderma Lung Disease Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1587 - 1591. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Allanore, D. Borderie, P. Hilliquin, A. Hernvann, M. Levacher, H. Lemarechal, O. G. Ekindjian, and A. Kahan Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells Rheumatology, October 1, 2001; 40(10): 1089 - 1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cavallo, L. Sabadini, L. Rollo, M. Catenaccio, S. Lorenzini, N. Pipitone, R. Marcolongo, and T. Yamamoto Nitric oxide synthesis in peripheral blood mononuclear and polymorphonuclear cells from patients with systemic sclerosis Rheumatology, December 1, 1999; 38(12): 1301 - 1304. [Full Text] [PDF] |
||||

